Investornewsbreaks Kairos Pharma Ltd. (NYSE American: KAPA) Highlights Preclinical Data On GITR Agonist KROS 101 At AACR-JCA Conference
Kairos Pharma (NYSE American: KAPA) presented preclinical data on its GITR agonist, KROS 101, during the plenary session of the AACR-JCA conference.
Le Lézard2d
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keros Therapeutics, Inc. - KROS
Pomerantz LLP is investigating claims on behalf of investors of Keros Therapeutics, Inc. ("Keros" or the "Company") . Such investors are advised to contact Danielle Peyton at [email protected] or ...
EITB4d
Van der Poelek zazpigarrenez irabazi du munduko ziklo-kros txapelketa
Mathieu van der Poelek zazpigarrenez irabazi du munduko ziklo-kros txapelketa, eta historian sartu da, Eric De Vlaeminck belgikarraren errekorra berdinduta. Txirrindulari nederlandarrak erakustaldia e ...
6,242 Shares in Keros Therapeutics, Inc. (NASDAQ:KROS) Bought by Exchange Traded Concepts LLC
Exchange Traded Concepts LLC acquired a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and ...
EITB5d
Fem van Empel, munduko ziklo-kros txapelduna hirugarrenez
Fem van Empel, munduko ziklo-kros txapelduna hirugarrenez. Fem van Empel nederlandarrak irabazi du munduko ziklo-kros ...
Keros Therapeutics, Inc. Being Investigated on Behalf of Keros Therapeutics, Inc. Investors. Contact Levi & Korsinsky For Details
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros ...